Why rescheduling LSD and psilocybin would transform research into treating depression and anxiety
Two decades’ worth of clinical research was first ignored and then forgotten; laboratories and careers were shut down; the War on Drugs claimed thousands of psychiatric patients as the first of its many civilian casualties.
If you’ve been paying attention recently you’ll know we are in the midst of a Psychedelic Renaissance, discovering the clinical value of many psychedelic drugs. It’s early days, but if psychedelic-assisted treatment proves to be even half as effective as early clinical trials suggest, it will blow all existing treatments for depression, anxiety, addiction, and many other conditions out of the water … So LSD and psilocybin weren’t placed on Schedule I due to lack of evidence of their therapeutic value. They were placed on Schedule I in the face of thousands of published scientific papers attesting to their therapeutic value, a move which was met with far more concerted opposition from scientists and psychiatrists than from hippies.
Original Article (Beckley Foundation):
Why rescheduling LSD and psilocybin would transform research into treating depression and anxiety
Artwork Fair Use: Sérgio Valle Duarte
